Abstract
Campylobacter spp. are major causes of gastrointestinal infections worldwide, and are commonly identified using modified-charcoal-cefoperazone-deoxycholate agar (mCCDA). However, the efficacy of this screening technique is often hindered by overgrowth of competing flora, such as extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. Thus, in the present study we supplemented mCCDA with a recently developed ESBL inhibitor, avibactam (A-mCCDA). We inoculated mCCDA and A-mCCDA plates with 25 strains each of Campylobacter spp. and ESBL-producing E. coli, and thereby determined that the optimum avibactam concentration required to inhibit ESBL-producing E. coli was 0.0625mg/L. At this concentration, a significantly higher proportion of Campylobacter spp. was isolated using A-mCCDA compared to that using mCCDA (P < 0.05). Thus, the results of the present study support the use of A-mCCDA to improve current Campylobacter screening methods.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
